期刊文献+

双特异抗体的研究进展 被引量:2

Recent advances in the development of bispecific antibodies
原文传递
导出
摘要 双特异抗体是指可以同时结合两个不同抗原或一个抗原不同表位的特殊抗体,目前已有3个双特异抗体批准上市,还有很多个双特异抗体处于临床或临床前研究阶段。文中就双特异抗体的发现、制备方法、结构类型和设计策略、作用机制以及目前研究现状进行综述。 Bispecific antibody(BsAbs) are antibodies(Abs) containing two different antigen-binding sites in one molecule. In the last decade, three BsAbs drugs have been approved for therapeutic use. Meanwhile there are a number of BsAbs in preclinical or clinical studies. In this review, we describe BsAb design, discovery, mechanism of action, and the recent research progress in developing BsAbs.
作者 叶金统 孟颂东 朱晓东 Jintong Ye;Songdong Meng;Xiaodong Zhu(Beijing Combio Pharmaceutical Co.,Ltd,Beijing 101111,China;CAS Key Laboratory of Pathogenic Microbiology and Immunology,Institute of Microbiology,Chinese Academy of Sciences,Beijing 100101,China)
出处 《生物工程学报》 CAS CSCD 北大核心 2020年第1期33-43,共11页 Chinese Journal of Biotechnology
基金 国家重大新药创制(No.2015ZX09102024)项目资助~~
关键词 双特异抗体 治疗性药物 抗肿瘤药 bispecific antibodies therapeutic drugs antitumor drug
  • 相关文献

参考文献1

二级参考文献29

  • 1GARBER K. Bispecific antibodies rise again[ J]. Nat Rev Drug Discov,2014, 13(11) : 799 -801. 被引量:1
  • 2SPASEVSKA I. An outlook on bispecific antibodies: methods of production and therapeutic benefits [ M ]. France:Ens de Lyon, 2013, 1-7. 被引量:1
  • 3TOPP MS, KUFER P, GOKBUGET N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy- refractoryminimal residual disease in B-lineage acute lymphoblas- tic leukemia patients results in high response rate and prolonged leukemia-free survival [ J]. J Clini Oncol, 2011, 29 ( 18 ) : 2493 - 2498. 被引量:1
  • 4TOPP MS, GKBUGET N, STEIN AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B- precursor acute lymphoblastic leukaemia: a muhicentre, single- arm, phase2 study[J]. Lancet Oncol, 2015, 16(1):57-66. 被引量:1
  • 5KONTERMANN RE, BRINKMANN U- Bispecific antibodies [J]. Drug Discovery Today, 2015, 20(7): 838-847. 被引量:1
  • 6ZEIDLER R, REISBACH G, WOLLENBERG B, et al. Simulta- neous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing [J]. Jlmmunol, 1999, 163(3): 1246-1252. 被引量:1
  • 7HEISS MM, MURAWA P, KORALEWSKI P, et al. The trifune- tional antibody catumaxomab for the treatment of malignant ascites due to epithelial eancer: Results of a prospective randomized phase II/III trial[ J ]. Int J Cancer J Int Cancer, 2010, 127 (9) : 2209 - 2221. 被引量:1
  • 8BUHMANN R, MICHAEL S, JUERGEN H, et al. Immunother- apy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in re- lapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation : study protocol of an investigator-driven, open-la- bel, non-randomized, uncontrolled, dose-escalating Phase I/II- trial[J]. J Translat Med, 2013, 11:160. 被引量:1
  • 9RIDGWAY JB, PRESTA LG, CARTER P. ' Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodime- rization[J]. ProteinEng, 1996, 9(7): 617 -621. 被引量:1
  • 10CARTER P. Bispecific human IgG by design [ J]. J Immunol Met, 2001, 248(1 -2): 7-15. 被引量:1

共引文献4

同被引文献13

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部